Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPIC: BP Reduction in Heart Failure
NCT01255475Phase 3Completed
- Sponsor
- Universidade de São Paulo
- Start
- Jan 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydralazine and amlodipine in heart failure (HF) (2 arms), sponsored by Universidade de São Paulo. Primary endpoints: Any cause mortality at 12 months and Unplanned hospital admission from any cause at 12 months. Started Jan 2011; status: completed.
02
Drugs
hydralazineamlodipine
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT01255475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01255475.